Pelthos Therapeutics Inc. (PTHS)
The price, the headline numbers and the latest news, in one place.
Pelthos Therapeutics Inc. (PTHS) Stock Price, Analysis & Data
| Bid | 26.29 |
| Market Cap | 101.72M |
| Revenue (ttm) | 43.3M |
| Net Income (ttm) | -86.39M |
| 3.13 | |
| -28.63 | |
| n/a | |
| -4.68 | |
| P/B (ttm) | -65.77 |
| P/S (ttm) | 2.35 |
| Earnings Date | Nov 12, 2026 |
| Ask | 27.52 |
| Volume | 25,069 |
| Avg. Volume (20D) | 51,063 |
| Open | 27.09 |
| Previous Close | 26.62 |
| Day's Range | 26.38 - 28.17 |
| 52-Week Range | 18.19 - 37.50 |
| Analyst | Strong Buy |
| Price Target | 50 (87.27%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PTHS
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months ...
Financial Performance
In 2025, Pelthos Therapeutics's revenue was 16.8M, an increase of undefined% compared to the previous year's 0. Earnings were -43.32M, an increase of 444.55%.
Financial StatementsAnalyst Forecast
According to 7 analyst ratings, the average rating for PTHS stock is "Strong Buy". The 12-month stock price forecast is 50, which is upside of 87.27% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $10.91M misses estimates by $0, with Infinity% YoY growth.
- EPS of -3.79 misses estimates by -0.84, with 29.55% YoY growth.
Analysts project revenue of ... Upgrade
